BS_GAGRGSSX
ATRT
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ATRT
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ATRT
- overall_survival_months
- 36.10381077529566
- age_years
- 1.575
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.676
- INTERFERON_GAMMA_RESPONSE+0.637
- ALLOGRAFT_REJECTION+0.555
- MYC_TARGETS_V2+0.497
- IL6_JAK_STAT3_SIGNALING+0.493
- INFLAMMATORY_RESPONSE+0.490
- E2F_TARGETS+0.401
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.401
- COMPLEMENT+0.370
- ANGIOGENESIS+0.344
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.435
- PROTEIN_SECRETION-0.313
- UV_RESPONSE_DN-0.272
- OXIDATIVE_PHOSPHORYLATION-0.250
- BILE_ACID_METABOLISM-0.245
- PANCREAS_BETA_CELLS-0.245
- ADIPOGENESIS-0.219
- HEME_METABOLISM-0.208
- NOTCH_SIGNALING-0.203
- WNT_BETA_CATENIN_SIGNALING-0.147
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168610 | — | — | 0.894 |
| 2 | TCGA-OR-A5JB-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.878 |
| 3 | 346fe4c0-2ea0-45b4-8863-b0f9e7756ad6 | — | — | 0.858 |
| 4 | SRR817658 | GTEX | — | 0.853 |
| 5 | TCGA-GU-A766-01A-11R-A32O-07 | — | — | 0.844 |
| 6 | SRR819346 | GTEX | — | 0.843 |
| 7 | SRR934894 | — | — | 0.839 |
| 8 | TCGA-66-2782-01A-01R-0851-07 | — | cohortSQ1 | 0.838 |
| 9 | BS_QX12J6W1 | ATRT | — | 0.838 |
| 10 | SRR810571 | GTEX | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.676 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.637 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.555 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.497 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.493 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.401 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.401 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.344 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.343 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.323 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.283 | Idelalisib | — uncovered |
| COAGULATION | 0.281 | Binimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.265 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.233 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.203 | Inavolisib | — uncovered |
| APOPTOSIS | 0.192 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.186 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.174 | Idelalisib | — uncovered |